Elevance Health Inc.

ELV

NYSE

Healthcare

Medical - Healthcare Plans

Indianapolis, IN, US104,200 employeeselevancehealth.com

$300.96

+2.46(0.82%)

Mkt Cap $66.4B

$274.66

$441.17

52-Week Range

At A Glance

Elevance Health Inc.

Revenue is primarily driven by Reportable Segments (77.3%) and Total Carelon (9.7%).

Most recently: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2 (2026-02-26).

$66.4B

Market Cap

$198.1B

Revenue

$5.6B

Net Income

Employees104,200

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segments77.3%($547.5B)

Total Carelon9.7%($69.0B)

Carelon Rx Segment9.4%($66.6B)

Health Benefits Segment3.2%($22.3B)

Carelon Services Segment0.3%($2.4B)

Corporate And Other0%($34M)

Activity

What Changed Recently

Management Change

Feb 25, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2

Financial Results

Jan 27, 2026

or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth b

Regulation FD

Mar 9, 2026

Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) expect to speak with investors and analysts over the next week. During these meetings

Other Event

Mar 1, 2026

Regulation FD Disclosure On February 27, 2026, Elevance Health, Inc. (the “Company”) was notified by the Centers for Medicare & Medicaid Services (“CMS”) of its

Peer Companies

Company	Price	Change	Market Cap	P/E
GSKGSK plc	$56.62	+1.12%	$114.0B	13.7
CVSCVS Health Corporation	$73.56	+1.48%	$93.6B	51.2
REGNRegeneron Pharmaceuticals...	$761.17	-2.07%	$79.1B	16.8
CICigna Corporation	$270.07	+1.03%	$72.1B	11.7
CORCencora, Inc.	$324.26	+2.08%	$63.1B	38.3
BDXBecton, Dickinson and Com...	$154.72	-1.03%	$56.1B	25.3
ZTSZoetis Inc.	$117.65	+0.31%	$51.8B	18.9
IDXXIDEXX Laboratories, Inc.	$570.15	+0.97%	$45.4B	43.7

Analyst View

Company Profile

CIK0001156039

ISINUS0367521038

CUSIP036752103

Phone800 331 1476

Address220 Virginia Avenue, Indianapolis, IN, 46204, US

SEC EDGAR